Ultragenyx Pharmaceutical (NASDAQ:RARE) Releases Quarterly Earnings Results, Misses Estimates By $0.07 EPS

Ultragenyx Pharmaceutical (NASDAQ:RARE) posted its earnings results on Thursday. The biopharmaceutical company reported ($1.39) EPS for the quarter, missing analysts’ consensus estimates of ($1.32) by ($0.07), Zacks reports. Ultragenyx Pharmaceutical had a negative net margin of 106.93% and a negative return on equity of 187.12%.

Ultragenyx Pharmaceutical Stock Up 0.0 %

Shares of Ultragenyx Pharmaceutical stock traded up $0.01 during trading on Friday, reaching $43.53. The company’s stock had a trading volume of 301,912 shares, compared to its average volume of 876,440. The business has a 50 day moving average price of $43.81 and a 200-day moving average price of $49.59. Ultragenyx Pharmaceutical has a 12-month low of $37.02 and a 12-month high of $60.37. The company has a market capitalization of $4.02 billion, a P/E ratio of -6.61 and a beta of 0.60.

Wall Street Analyst Weigh In

RARE has been the topic of several research reports. Wedbush reaffirmed a “neutral” rating and set a $48.00 price objective (up previously from $46.00) on shares of Ultragenyx Pharmaceutical in a report on Monday, January 13th. Canaccord Genuity Group restated a “buy” rating and set a $121.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, November 12th. Wells Fargo & Company boosted their price objective on Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the company an “overweight” rating in a research note on Friday, December 20th. HC Wainwright restated a “buy” rating and set a $95.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Friday. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $118.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, January 22nd. One analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $92.43.

Insiders Place Their Bets

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 11,727 shares of the business’s stock in a transaction on Monday, December 30th. The shares were sold at an average price of $42.23, for a total transaction of $495,231.21. Following the sale, the chief executive officer now directly owns 2,183,985 shares in the company, valued at approximately $92,229,686.55. The trade was a 0.53 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 5.80% of the stock is currently owned by company insiders.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.